Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Cantor Fitzgerald

Generated: December 14, 2018

DrugPatentWatch Database Preview

Claims for Patent: 6,133,260

« Back to Dashboard

Summary for Patent: 6,133,260
Title: Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases
Abstract:The invention relates to the use of quinolone- and naphthyridonecarboxylic acid derivatives which are substituted in the 7-position by a 2-oxa-5,8-diazabicyclo[4.3.0]-non-8-yl) radical, and their pharmaceutically utilizable hydrates and/or salts for the therapy of Helicobacter pylori infections and the gastroduodenal disorders associated therewith.
Inventor(s): Matzke; Michael (Wuppertal, DE), Petersen; Uwe (Leverkusen, DE), Jaetsch; Thomas (Koln, DE), Bartel; Stephan (Kurten, DE), Schenke; Thomas (Bergisch Gladbach, DE), Himmler; Thomas (Odenthal-Globusch, DE), Baasner; Bernd (Bergisch Gladbach, DE), Werling; Hans-Otto (Wuppertal, DE), Schaller; Klaus (Wuppertal, DE), Labischinski; Harald (Wuppertal, DE)
Assignee: Bayer Aktiengesellschaft (Leverkusen, DE)
Application Number:09/319,888
Patent Claims: 1. A compound which is 8-cyano-1-cyclopropyl-6-fluoro-7-((1S,6S)-2-oxa-5,8-diazabicyclo [4.3.0]-non-8-yl)-1,4-dihydro-4-oxo-3-quinoline carboxylic acid of the formula: ##STR43## or a pharmaceutically utilizable hydrate and/or salt thereof.

2. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically utilizable carrier.

3. A method for treating a Helicobacter pylori infection and/or a gastroduodenal disorder associated with a Helicobacter pylori infection, said method comprising administering to a patient an effective amount therefor of the compound according to claim 1.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
US Department of Justice
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.